NCT05850286View on ClinicalTrials.gov

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2027

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

anti-BCMA CAR-T

Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.

DRUG

VRD-based Regimen

Bortezomib, Lenalidomide and Dexamethasone

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER